Advitech and PL Thomas (PLT) have concluded a non-exclusive distribution agreement with a yearly commitment for Advitech’s XP-828L ingredient, a patent-pending composition consisting of growth factors, especially TGF-
InterStim therapy is a reversible treatment for patients with fecal incontinence after conservative treatments have failed. Once approved by the FDA, InterStim therapy for fecal incontinence will be
The investment, led by Inventages, will advance continued development of the Neuroptix Sapphire diagnostic platform and related technologies. The Neuroptix Sapphire system consists of a non-contact optical device
Dr Khvorova has previously served as chief scientific officer at Dharmacon, a developer and supplier of RNAi compounds. Prior to Dharmacon, Dr Khvorova served as research scientist with
Olmesartan medoxomil hydrochlorothiazide tablets, indicated for the treatment of high blood pressure, are the generic version of Daiichi Sankyo’s Benicar HCT. Mylan Pharmaceuticals has previously submitted its original
Under the terms of the agreement, AlphaRx will use its proprietary nano drug delivery platforms to formulate two injectable products targeting underserved medical conditions. These represent market opportunities
As part of the agreement, the Juvenile Diabetes Research Foundation (JDRF) will provide $1 million in first-year funding to support preclinical safety and efficacy testing. The partnership is
Mylan believes that it is the first company to file a substantially complete abbreviated new drug application (ANDA) containing a paragraph IV certification for the product. The company
The data showed encouraging and durable anti-tumor activity in the three expanded dose groups tested thus far, as measured by prostate specific antigen (PSA) declines, radiographic findings, circulating
The license provides Enigma with access to claims of US patent that describe methods for monitoring nucleic acid amplification in real-time. This is the first such license Applied
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.